Why is Balaxi Pharma falling/rising?

As of 13-Aug, Balaxi Pharmaceuticals Ltd is currently priced at 48.75, reflecting a slight increase of 0.18 or 0.37%. The stock's performance today is in line with its sector, although it is higher than the 5-day and 20-day moving averages but lower than the 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has gained 2.31%, contrasting with a decline of 0.49% over the past month. Despite this short-term uptick, the stock has significantly underperformed over the longer term, with a staggering drop of 55.83% in the last year and 44.39% over the past three years. The company's fundamentals show strong long-term potential with an average Return on Equity (ROE) of 30.97% and a very attractive valuation, yet it has faced negative results recently, including a 70.93% drop in profit before tax and a 95.5% decline in profit after tax for the quarter ending June 25. Additionally, institutional investor participation has decreased, indicating a lack of confidence among larger investors.
In the broader market context, Balaxi Pharmaceuticals' recent short-term return of 2.31% over the past week stands in stark contrast to the Sensex, which has only increased by 0.18% during the same period. However, the stock's long-term performance remains concerning, as it has consistently underperformed against the benchmark, generating a return of -55.83% in the last year compared to the Sensex's gain of 1.99%. This consistent underperformance, coupled with falling investor participation and disappointing financial results, suggests that while there may be some short-term gains, the overall outlook for Balaxi Pharmaceuticals remains negative.